Literature DB >> 32900609

Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?

Olivia Sgarbura1, Laurent Villeneuve2, Mohammad Alyami3, Naoual Bakrin4, Juan José Torrent5, Clarisse Eveno6, Martin Hübner7.   

Abstract

BACKGROUND: PIPAC is a new treatment modality for peritoneal cancer which has been practiced and evaluated until very recently by few academic centers in a highly standardized manner. Encouraging oncological outcomes and the safety profile have led to widespread adoption. The aim of this study was to assess current PIPAC practice in terms of technique, treatment and safety protocol, and indications.
METHODS: A standardized survey with 82 closed-ended questions was sent online to active PIPAC centers which were identified by help of PIPAC training centers and the regional distributors of the PIPAC-specific nebulizer. The survey inquired about center demographics (n = 8), technique (n = 34), treatment and safety protocol (n = 34), and indications (n = 6).
RESULTS: Overall, 62 out of 66 contacted PIPAC centers answered the survey (response rate 93%). 27 centers had performed >60 PIPAC procedures. A consensus higher than 70% was reached for 37 items (50%), and higher than 80% for 28 items (37.8%). The topics with the highest degree of consensus were safety and installation issues (93.5% and 80.65%) while chemotherapy and response evaluation were the least consensual topics (63.7 and 59.6%). The attitudes were not influenced by volume, PIPAC starting year, type of activity, or presence of peritoneal metastases program.
CONCLUSION: Homogeneous treatment standards of new techniques are important to guarantee safe implementation and practice but also to allow comparison between cohorts and multi-center analysis of merged data including registries. Efforts to avoid diversification of PIPAC practice include regular update of the PIPAC training curriculum, targeted research and a consensus statement.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Indications; PRGS; Peritoneal metastasis; Safety; Technique; Treatment protocol; ePIPAC

Mesh:

Substances:

Year:  2020        PMID: 32900609     DOI: 10.1016/j.ejso.2020.08.020

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  11 in total

Review 1.  The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review.

Authors:  Robin J Lurvink; Kurt Van der Speeten; Koen P Rovers; Ignace H J T de Hingh
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Body composition and immunonutritional status in patients treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) for gastrointestinal peritoneal metastases: a prospective single-center analysis.

Authors:  Stefano Rotolo; Andrea Di Giorgio; Marco Cintoni; Emanuele Rinninella; Marta Palombaro; Gabriele Pulcini; Carlo Alberto Schena; Vito Chiantera; Giuseppe Vizzielli; Antonio Gasbarrini; Fabio Pacelli; Maria Cristina Mele
Journal:  Pleura Peritoneum       Date:  2022-03-01

3.  Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.

Authors:  Abdelkader Taibi; Olivia Sgarbura; Martin Hübner; Sylvia M Bardet; Mohammed Alyami; Naoual Bakrin; Sylvaine Durand Fontanier; Clarisse Eveno; Johan Gagniere; Basile Pache; Marc Pocard; François Quenet; Hugo Teixeira Farinha; Emilie Thibaudeau; Frederic Dumont; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2022-03-22       Impact factor: 4.339

4.  Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases.

Authors:  Aurélie Balmer; Daniel Clerc; Laura Toussaint; Olivia Sgarbura; Abdelkader Taïbi; Martin Hübner; Hugo Teixeira Farinha
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

5.  Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Olivia Sgarbura; Clarisse Eveno; Mohammad Alyami; Naoual Bakrin; Delia Cortes Guiral; Wim Ceelen; Xavier Delgadillo; Thanh Dellinger; Andrea Di Giorgio; Amaniel Kefleyesus; Vladimir Khomiakov; Michael Bau Mortensen; Jamie Murphy; Marc Pocard; Marc Reymond; Manuela Robella; Koen P Rovers; Jimmy So; S P Somashekhar; Clemens Tempfer; Kurt Van der Speeten; Laurent Villeneuve; Wei Peng Yong; Martin Hübner
Journal:  Pleura Peritoneum       Date:  2022-03-01

6.  Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort.

Authors:  Willem J Koemans; Robin J Lurvink; Cecile Grootscholten; Rob H A Verhoeven; Ignace H de Hingh; Johanna W van Sandick
Journal:  Gastric Cancer       Date:  2021-01-25       Impact factor: 7.370

7.  First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).

Authors:  Robin J Lurvink; Paulien Rauwerdink; Koen P Rovers; Emma C E Wassenaar; Maarten J Deenen; Joost Nederend; Clément J R Huysentruyt; Iris van 't Erve; Remond J A Fijneman; Erik J R J van der Hoeven; Cornelis A Seldenrijk; Alexander Constantinides; Onno Kranenburg; Maartje Los; Karin H Herbschleb; Anna M J Thijs; Geert-Jan M Creemers; Jacobus W A Burger; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh
Journal:  BMJ Open       Date:  2021-03-30       Impact factor: 2.692

8.  Histological regression of gastrointestinal peritoneal metastases after systemic chemotherapy.

Authors:  Laura Toussaint; Hugo Teixeira Farinha; Jean-Luc Barras; Nicolas Demartines; Christine Sempoux; Martin Hübner
Journal:  Pleura Peritoneum       Date:  2021-07-15

9.  Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC).

Authors:  Robin J Lurvink; Koen P Rovers; Emma C E Wassenaar; Checca Bakkers; Jacobus W A Burger; Geert-Jan M Creemers; Maartje Los; Floortje Mols; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh
Journal:  Surg Endosc       Date:  2021-11-10       Impact factor: 3.453

10.  Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Mojib Fallah; Sönke Detlefsen; Alan P Ainsworth; Claus W Fristrup; Michael B Mortensen; Per Pfeiffer; Line S Tarpgaard; Martin Graversen
Journal:  Pleura Peritoneum       Date:  2022-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.